- by Rowan WalrathArtificial intelligence start-up PostEra will help the drugmaker design new payloads
- by Brianna BarbuSulfenylnitrene reagent expands N-heterocycles by a single N atom
- by Payal Dhar, special to C&ENThe mouse models used for preclinical studies may not be appropriate for predicting responses in humans
- by Rowan WalrathGEMMA Biotherapeutics will put the money toward rare disease drugs
- by Max BarnhartHuman endogenous retroviruses, or HERVs, are bits of ancient viruses hibernating in our DNA
- by Sarah Braner
- by Aayushi PratapSwiss company says the divestment will help it focus on pharmaceutical services
- by Asher Mullard, special to C&ENSmall molecules hint at a new treatment option for the inherited blood disorder
- by Bethany HalfordSmall molecule’s target is similar in many coronaviruses
- by Rowan WalrathThe pharma giant will acquire oral peptide developer Nimble Therapeutics
Making chemistry accessible and relevant.